Clinical trial
A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma
NCT00102752 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma
- Lead sponsor
- Threshold Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 31, 2004
- Completion date
- July 31, 2007
- Enrollment
- 47
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.